Rare disease biotech Beren adds $300M from new financings

June 10, 2026 02:49 PM EDT StartupsR&DFDA+ Now at FDA’s doorstep, Beren Ther­a­peu­tics tacks on $300M in new fi­nanc­ings Max Bayer Senior Reporter Anx­ious­ly await­ing an FDA de­ci­sion this fall, Beren Ther­a­peu­tics has added $300 mil­lion in new cap­i­tal to help launch its rare dis­ease drug. The biotech … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER